22nd Dec 2021 14:23
(Correcting spelling of name of CEO Arron Tolley.)
Aptamer Group PLC - York-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Starts trading on AIM market in London on Wednesday, after raising GBP10.8 million in its initial public offering. Has market capitalisation of GBP80 million on admission at its IPO price of 117 pence, but stock is quoted at 144.5p Wednesday afternoon, up 24%. Spark Advisory Partners Ltd is its nominated adviser and Liberum Capital its broker.
Company focuses on aptamer discovery services and developing aptamer-based reagents. Aptamers are synthetic nucleic acid-based biological molecules, selected based on their specific characteristics to bind to a "target" of interest, such as proteins, cells, viruses or small molecules.
"This listing marks an important step in our journey as we solidify our position as the leading provider of aptamer discovery and selection services and the development of aptamer-based reagents," says Chief Executive Officer Arron Tolley.
By Tom Waite; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Aptamer Group